Medical technology company Therma Bright Inc. has achieved a significant milestone with its Venowave VW5 compression therapy device receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States. The FDA-designated Durable Medical Equipment device provides patients with a lightweight and compact solution for managing post-operative recovery, pain, and swelling issues through simple and comfortable treatment.
The company's market position has been strengthened through strategic distribution partnerships with national medical device distributors. DME Authority has committed to a substantial inventory purchase, including an initial order of 1,750 Venowave VW5 units representing potential HCPCS code reimbursements of approximately $1.43 million. Another national distributor, Valor Medical, has placed an initial order for 100 units with potential for regular future purchases. These partnerships demonstrate growing market acceptance and create a foundation for broader distribution of the compression therapy technology.
The compression therapy market presents significant growth opportunities for Therma Bright. According to Straits Research, the global market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, with a compound annual growth rate of 7.30%. The company's position in this expanding market is strengthened by the Medicare reimbursement status of its flagship product, which addresses a critical need for portable, reimbursable compression therapy solutions.
Beyond the Venowave VW5, Therma Bright is developing additional innovative medical technologies that could expand its market presence. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. This technology represents a potential expansion into the growing field of remote patient monitoring and digital health solutions.
These developments position Therma Bright as an emerging player in the medical device technology sector with potential for continued expansion in both compression therapy and remote monitoring markets. The combination of Medicare reimbursement status, strategic distribution partnerships, and pipeline technologies creates multiple pathways for growth in healthcare markets that increasingly value portable, reimbursable medical devices and remote monitoring capabilities.
